The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | What remaining challenges are there in the management of rectal cancer?
Yuichiro Tsukada, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses unmet needs in the field of rectal cancer. Low-lying rectal cancer historically had few treatment options, and neoadjuvant chemotherapy is a promising therapeutic modality. Whilst relapse-free survival has improved, local recurrence has remained the same, and more research is needed to ameliorate this. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
